Although a recent meta-analysis revealed no increased risk of bone fracture among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors, a decline in bone mineral density and alteration of bone turnover markers have been reported (Ruanpeng et al., 2017). This evidence concerns the gene SLC5A2 and bone fracture.